97 related articles for article (PubMed ID: 20678563)
1. Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
Int J Pharm; 2010 Oct; 399(1-2):31-6. PubMed ID: 20678563
[TBL] [Abstract][Full Text] [Related]
2. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
3. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden TD
Cancer Res; 2000 Jul; 60(13):3389-93. PubMed ID: 10910044
[TBL] [Abstract][Full Text] [Related]
4. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y
Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336
[TBL] [Abstract][Full Text] [Related]
5. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
6. Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation.
Cui J; Li C; Wang L; Wang C; Yang H; Li Y; Zhang L; Zhang L; Guo W; Liang M
Int J Pharm; 2009 Feb; 368(1-2):24-30. PubMed ID: 18973800
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.
Abraham SA; Edwards K; Karlsson G; Hudon N; Mayer LD; Bally MB
J Control Release; 2004 May; 96(3):449-61. PubMed ID: 15120901
[TBL] [Abstract][Full Text] [Related]
8. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
9. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.
Zucker D; Andriyanov AV; Steiner A; Raviv U; Barenholz Y
J Control Release; 2012 Jun; 160(2):281-9. PubMed ID: 22019556
[TBL] [Abstract][Full Text] [Related]
10. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
Li C; Cui J; Wang C; Li Y; Zhang H; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
[TBL] [Abstract][Full Text] [Related]
11. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
Allen TM; Mehra T; Hansen C; Chin YC
Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
[TBL] [Abstract][Full Text] [Related]
12. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
13. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
Li CL; Cui JX; Wang CX; Zhang L; Li YH; Zhang L; Xiu X; Li YF; Wei N
Int J Pharm; 2010 May; 391(1-2):230-6. PubMed ID: 20214962
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel.
Chang G; Ci T; Yu L; Ding J
J Control Release; 2011 Nov; 156(1):21-7. PubMed ID: 21777632
[TBL] [Abstract][Full Text] [Related]
15. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
16. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
Jain A; Jain SK
Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
[TBL] [Abstract][Full Text] [Related]
17. Optimization of liposomal topotecan for use in treating neuroblastoma.
Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
[TBL] [Abstract][Full Text] [Related]
18. Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS.
Li N; Han X; Yang J; Gui L; Song Y; Du P; Shi Y
J Pharm Biomed Anal; 2013 Mar; 76():252-6. PubMed ID: 23354352
[TBL] [Abstract][Full Text] [Related]
19. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.
Gilabert-Oriol R; Chernov L; Anantha M; Dragowska WH; Bally MB
Drug Deliv Transl Res; 2017 Aug; 7(4):544-557. PubMed ID: 28432657
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously.
Qi X; Fan Y; He H; Wu Z
Carbohydr Polym; 2015 Aug; 126():231-9. PubMed ID: 25933544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]